Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 31;101(10):adv00583.
doi: 10.2340/actadv.v101.350.

Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis

Affiliations

Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis

Dominika Kwiatkowska et al. Acta Derm Venereol. .

Abstract

Pruritus can be defined as an unpleasant sensation that evokes a desire to scratch and significantly impairs patients' quality of life. Pruritus is widely observed in many dermatoses, including mastocytosis, a rare disease characterized by abnormal accumulation of mast cells, which can involve skin, bone marrow, and other organs. Increasing evidence highlights the role of mast cells in neurogenic inflammation and itching. Mast cells release various pruritogenic mediators, initiating subsequent mutual communication with specific nociceptors on sensory nerve fibres. Among important mediators released by mast cells that induce pruritus, one can distinguish histamine, serotonin, proteases, as well as various cytokines. During neuronal-induced inflammation, mast cells may respond to numerous mediators, including neuropeptides, such as substance P, neurokinin A, calcitonin gene-related peptide, endothelin 1, and nerve growth factor. Currently, treatment of pruritus in mastocytosis is focused on alleviating the effects of mediators secreted by mast cells. However, a deeper understanding of the intricacies of the neurobiology of this disease could help to provide better treatment options for patients.

PubMed Disclaimer

Conflict of interest statement

DK has no conflicts of interest to declare.

AR has worked as a consultant or speaker for AbbVie, Bioderma, Celgene, Chema Elektromet, Eli Lilly, Galderma, Janssen, Leo Pharma, Medac, Menlo Therapeutics, Novartis, Pierre-Fabre, Sandoz, and Trevi, and participated as principal investigator or subinvestigator in clinical trials sponsored by AbbVie, Drug Delivery Solutions Ltd, Galderma, Genentech, Janssen, Kymab Limited, Leo Pharma, Menlo Therapeutics, MetrioPharm, MSD, Novartis, Pfizer, and Trevi.

Figures

Fig. 1
Fig. 1
Flowchart of PubMed database search.
Fig. 2
Fig. 2
Proposed model of the functional interaction between mast cells and the synapse of the sensory nerve in the skin. Immunoglobulin E (IgE) bounds antigens (different allergens) and triggers the IgE receptor FcεRI signalling pathway, which results in mast cell degranulation. Mast cells release various mediators, such as chymase, tryptase, serotonin, histamine, and interleukins (including interleukin (IL)-31). Transmitters released from mast cells interact with their specific receptors (protease-activated receptor (PAR-2), serotonin receptor 5HTR, histamine receptor (HR), interleukin 31 receptor (IL-31R)) on nerve terminals, which leads to direct activation of pruriceptors. Stimulation of PAR-2 receptors leads to coactivation of transient receptor potential channels (TRP channels). In turn, activated nerve fibres release several mediators, including neuropeptides, such as calcitonin gene-related peptide (CGRP), substance P, nerve growth factor (NGF) and neurokinin 1, which elicit feedback activation of the mast cell through respective receptors (Masrelated G protein-coupled receptor-X2 (MGPRX2), neurokinin 1 receptor (NK-1R), tropomyosin receptor kinase A (TrkA)). CALCRL/RAMP1: calcitonin receptor-like receptor/receptor activity-modifying protein 1; DRG: dorsal root ganglion.

Similar articles

Cited by

References

    1. Reich A, Szepietowski JC. Diagnostic procedures of itch. Curr Probl Dermatol 2016; 50: 24–28. - PubMed
    1. Carter MC, Metcalfe DD, Komarow HD. Mastocytosis. Immunol Allergy Clin North Am 2014; 34: 181–196. - PMC - PubMed
    1. Le M, Miedzybrodzki B, Olynych T, Chapdelaine H, Ben-Shoshan M. Natural history and treatment of cutaneous and systemic mastocytosis. Postgrad Med 2017; 129: 896–901. - PubMed
    1. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017; 129: 1420–1427. - PMC - PubMed
    1. Bulat V, Mihić LL, Šitum M, Buljan M, Blajić I, Pušić J. Most common clinical presentations of cutaneous mastocytosis. Acta Clin Croat Suppl 2009; 48: 59–64. - PubMed

LinkOut - more resources